Future multicenter, multi-platform studies should be conducted to recruit larger cohorts of NAT-resistant ESCC patients, which would enable definitive demonstration of the relationship between CTSC overexpression and NAT resistance. The gene discussed is BRD2; the disease is esophageal squamous cell carcinoma.